National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...
A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. John Meehan and his wife, Mary Ellen, moved to Charlotte ...
Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and ...
Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...
Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects. Compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback